Adding vorasidenib to temozolomide after radiation for grade 3 astrocytoma
Original title: Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a large, late stage trial, but it is still a test and not treatment your own doctor can give you.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial is testing whether adding a drug called vorasidenib: A medicine approved in 2024 for some people with a grade 2 glioma. The glioma has to have an IDH change. The medicine acts on that change itself. It is taken after surgery. See the glossary to usual chemotherapy helps people with newly diagnosed grade 3 astrocytoma.
Who this trial is for. This trial is for people newly diagnosed with grade 3 astrocytoma who have had radiation. Everyone gets the usual chemotherapy drug, temozolomide: A chemotherapy taken as a capsule, used for some brain tumors. Your team checks your blood counts while you are on it. See the glossary. Some people also get vorasidenib: A medicine approved in 2024 for some people with a grade 2 glioma. The glioma has to have an IDH change. The medicine acts on that change itself. It is taken after surgery. See the glossary. Others get a placebo instead.
Where it stands. The trial has not reported results. It is measuring whether temozolomide: A chemotherapy taken as a capsule, used for some brain tumors. Your team checks your blood counts while you are on it. See the glossary plus vorasidenib: A medicine approved in 2024 for some people with a grade 2 glioma. The glioma has to have an IDH change. The medicine acts on that change itself. It is taken after surgery. See the glossary works better than temozolomide alone after radiation. That answer is not in yet.
What this means, and what it doesn't
What it could mean: temozolomide: A chemotherapy taken as a capsule, used for some brain tumors. Your team checks your blood counts while you are on it. See the glossary damages the DNA inside cells. That may kill tumor cells or slow tumor growth. vorasidenib: A medicine approved in 2024 for some people with a grade 2 glioma. The glioma has to have an IDH change. The medicine acts on that change itself. It is taken after surgery. See the glossary blocks proteins made by changed IDH gene change: A small change in a tumor's IDH gene. It is the first thing your team looks at when naming an adult glioma, and it can affect which treatments are offered. Your pathology report says whether your tumor has it. See the glossary and IDH2 genes, which may help stop tumor cells from growing. Researchers want to see if using both is better than temozolomide by itself. If this sounds like your situation, you can ask your care team about it.
What it doesn't mean: This does not mean vorasidenib: A medicine approved in 2024 for some people with a grade 2 glioma. The glioma has to have an IDH change. The medicine acts on that change itself. It is taken after surgery. See the glossary is a proven treatment for grade 3 astrocytoma. A trial is a test. The researchers do not yet know if adding this drug helps. Joining a trial is not a guarantee that you will do better. It is not a promise of a cure. Whether anyone can join is decided by the trial team.
Source: ClinicalTrials.gov, August 5, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.